

Elia Sechi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9430702/publications.pdf>

Version: 2024-02-01

67
papers

1,987
citations

361045

20
h-index

288905

40
g-index

69
all docs

69
docs citations

69
times ranked

1605
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. <i>JAMA Neurology</i> , 2019, 76, 301.	4.5	243
2	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. <i>JAMA Neurology</i> , 2021, 78, 741.	4.5	124
3	Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. <i>Journal of Neurology</i> , 2017, 264, 2420-2430.	1.8	120
4	Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults. <i>Nutrition Reviews</i> , 2016, 74, 281-300.	2.6	113
5	Anatomical variability of the lateral femoral cutaneous nerve: Findings from a surgical series. <i>Clinical Anatomy</i> , 2009, 22, 365-370.	1.5	96
6	Neurologic autoimmunity and immune checkpoint inhibitors. <i>Neurology</i> , 2020, 95, e2442-e2452.	1.5	94
7	Clinical spectrum of high-titre GAD65 antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 645-654.	0.9	84
8	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	84
9	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. <i>Neurology</i> , 2021, 97, e1097-e1109.	1.5	77
10	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. <i>Multiple Sclerosis Journal</i> , 2021, 27, 303-308.	1.4	64
11	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 384-390.	0.9	55
12	Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 488-490.	0.9	54
13	Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder. <i>JAMA Neurology</i> , 2020, 77, 1575.	4.5	52
14	LG11 antibody encephalitis: acute treatment comparisons and outcome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 309-315.	0.9	48
15	Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis. <i>Journal of Neurology</i> , 2019, 266, 1643-1648.	1.8	41
16	Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. <i>Clinical Chemistry</i> , 2020, 66, 1496-1509.	1.5	41
17	Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1293-1296.	0.9	40
18	Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. <i>Frontiers in Neurology</i> , 2021, 12, 673339.	1.1	40

#	ARTICLE	IF	CITATIONS
19	The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101487.	0.9	35
20	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. <i>Neurology</i> , 2019, 93, e414-e420.	1.5	26
21	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. <i>Neurology</i> , 2021, 97, e1351-e1358.	1.5	25
22	Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103424.	0.9	25
23	Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD. <i>Journal of Neuroimmunology</i> , 2020, 338, 577110.	1.1	23
24	Unilateral motor progression in MS. <i>Neurology</i> , 2019, 93, e628-e634.	1.5	22
25	Utility of MRI Enhancement Pattern in Myelopathies With Longitudinally Extensive T2 Lesions. <i>Neurology: Clinical Practice</i> , 2021, 11, e601-e611.	0.8	21
26	Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102638.	0.9	20
27	Diagnosis and Management of Autoimmune Dementia. <i>Current Treatment Options in Neurology</i> , 2019, 21, 11.	0.7	16
28	Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease. <i>Frontiers in Neurology</i> , 2022, 13, 866824.	1.1	16
29	Late presentation of NMOSD as rapidly progressive leukoencephalopathy with atypical clinical and radiological findings. <i>Multiple Sclerosis Journal</i> , 2018, 24, 685-688.	1.4	15
30	Serum neurofilament light chain studies in neurological disorders, hints for interpretation. <i>Journal of the Neurological Sciences</i> , 2020, 416, 116986.	0.3	15
31	FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis With Seizures (FLAMES): Is immunotherapy always needed to put out the fire?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102283.	0.9	15
32	Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642199890.	1.5	15
33	HERV-K Modulates the Immune Response in ALS Patients. <i>Microorganisms</i> , 2021, 9, 1784.	1.6	15
34	Exploratory screening for Fabry's disease in young adults with cerebrovascular disorders in northern Sardinia. <i>BMC Neurology</i> , 2015, 15, 256.	0.8	14
35	Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination. <i>Vaccines</i> , 2021, 9, 1502.	2.1	13
36	<i>Mycobacterium avium</i> subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder. <i>Journal of Neuroimmunology</i> , 2018, 318, 97-102.	1.1	12

#	ARTICLE	IF	CITATIONS
37	Beyond Giant Cell Arteritis and Takayasu's Arteritis: Secondary Large Vessel Vasculitis and Vasculitis Mimickers. <i>Current Rheumatology Reports</i> , 2020, 22, 88.	2.1	12
38	Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2021, 16, 381-394.	0.5	12
39	Ceftriaxone for Alexander's Disease: A Four-Year Follow-Up. <i>JIMD Reports</i> , 2012, 9, 67-71.	0.7	11
40	Teaching Neuro Images: Subacute encephalopathy in a young woman with THTR2 gene mutation. <i>Neurology</i> , 2015, 85, e108-9.	1.5	11
41	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110526.	0.5	11
42	Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731774242.	0.5	10
43	Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103827.	0.9	10
44	Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis. <i>Stroke</i> , 2021, 52, 645-654.	1.0	9
45	Unfavorable outcome in highly relapsing MOGAD encephalitis. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117088.	0.3	8
46	Evaluation and Management of Acute Myelopathy. <i>Seminars in Neurology</i> , 2021, 41, 511-529.	0.5	8
47	Paradoxical Effect of Levetiracetam in Newly Diagnosed Type II Focal Cortical Dysplasia. <i>Clinical Neuropharmacology</i> , 2016, 39, 265-268.	0.2	7
48	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 667-673.	1.4	7
49	Exposure to TNF inhibitors is rare at MOGAD presentation. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120044.	0.3	7
50	Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110487.	0.5	5
51	Clinicopathologic features of folate-deficiency neuropathy. <i>Neurology</i> , 2015, 85, 1090-1091.	1.5	4
52	Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and pathophysiological potential. <i>Journal of Circulating Biomarkers</i> , 2019, 8, 184945441987591.	0.8	4
53	Hypertrophic olivary degeneration mimics relapse in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2019, 92, 343-344.	1.5	4
54	Area postrema syndrome in autoimmune GFAP astrocytopathy. <i>Multiple Sclerosis Journal</i> , 2020, 26, 255-256.	1.4	4

#	ARTICLE	IF	CITATIONS
55	Spinal arteriovenous fistula's often misdiagnosed as myelitis; can we stem the flow?. Journal of the Neurological Sciences, 2020, 413, 116868.	0.3	4
56	Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 895-902.	1.4	4
57	Restless legs syndrome and cerebrovascular disease. Lancet Neurology, The, 2013, 12, 734.	4.9	3
58	Inflammatory activity following motor progression due to critical CNS demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 1037-1045.	1.4	3
59	Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2021, 358, 577666.	1.1	3
60	Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis. Neurology, 0, , 10.1212/WNL.000000000200837.	1.5	3
61	Neuralgic amyotrophy mimicking Vernet syndrome. Journal of the Neurological Sciences, 2016, 362, 230-231.	0.3	2
62	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurology, The, 2018, 17, 498-499.	4.9	2
63	Neurochondrin immunoglobulin G “ Associated myelopathy “ Ataxia syndrome. Journal of the Neurological Sciences, 2021, , 120058.	0.3	2
64	Rasagiline Withdrawal Syndrome in Parkinson’s Disease. Brain Sciences, 2022, 12, 219.	1.1	2
65	Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110521.	0.5	1
66	Longitudinally Extensive Spinal Cord Lesions Disclosing Occult Systemic Sarcoidosis. JAMA Neurology, 2016, 73, 600.	4.5	0
67	Diagnostic features of initial demyelinating events associated with serum MOG-IgG. Journal of Neuroimmunology, 2020, 344, 577260.	1.1	0